In addition, there were 5 cHL patients in the RP2D cohort relapsed (defined as progression after 3 months from the last dose of PD-1) after PD-(L)1 blockade, and 3 of them responded to the study treatment, with an ORR of 60% (Supplementary Fig. 2D and Supplementary Table 9). This evidence concerns the gene CD274 and classic Hodgkin lymphoma.